SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

May 25, 2020SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases
May 19, 2020Majoritetsägare i SynAct Pharma förlänger lock-up
May 13, 2020Kommunike från årsstämma i SynAct Pharma AB (publ)
May 5, 2020SynAct Pharma AB offentliggör delårsrapport för första kvartalet 2020

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit

Calendar

June 8, 2020 - June 11, 2020Bio International Convention
October 8, 2020Sedermeradagen Gothenburg
October 26, 2020 - October 28, 2020Bio Europe 2020

Subscribe to our press releases